Table 2.
Univariate and multivariate analyses for PFS and OS in the 36 patients with available tissue analysis results
| Progression-free survival | Overall survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (≥ 65 years vs. < 65 years) | 0.78 (0.36–1.70) | 0.534 | 0.39 (0.17–0.92) | 0.032 | 0.33 (0.14–0.78) | 0.012 | ||
| Sex (male vs. female) | 0.76 (0.35–1.67) | 0.501 | 0.60 (0.28–1.30) | 0.197 | ||||
| Tx. (nivolumab vs. placebo) | 0.57 (0.27–1.22) | 0.149 | 0.79 (0.36–1.74) | 0.561 | 0.51 (0.25–1.05) | 0.069 | 0.62 (0.30–1.29) | 0.201 |
| Prior gastrectomy (yes vs. no) | 0.98 (0.48–1.99) | 0.948 | 0.82 (0.40–1.69) | 0.594 | ||||
| HER2 (positive vs. negative) | 0.77 (0.35–1.73) | 0.532 | 0.57 (0.24–1.34) | 0.198 | ||||
| Number of metastatic organs (< 2 vs. ≥ 2) | 0.69 (0.35–1.39) | 0.303 | 0.85 (0.42–1.72) | 0.657 | ||||
| Treatment line (3rd line vs. ≥ 4th line) | 0.69 (0.33–1.42) | 0.311 | 0.57 (0.26–1.24) | 0.158 | ||||
| Baseline blood NLR (≤ 2.9 vs. > 2.9) | 0.57 (0.28–1.15) | 0.115 | 0.46 (0.22–0.95) | 0.037 | 0.60 (0.30–1.22) | 0.160 | ||
| Baseline serum Na (≥ 135 mmol/L vs. < 135 mmol/L) | 0.39 (0.16–0.93) | 0.033 | 0.50 (0.19–1.30) | 0.156 | 0.39 (0.17–0.92) | 0.031 | 0.82 (0.28–2.39) | 0.721 |
| Tumor PD-L1 CPS (≥ 1% vs. < 1%) | 0.37 (0.17–0.83) | 0.016 | 0.32 (0.14–0.72) | 0.006 | 0.56 (0.26–1.20) | 0.136 | 0.44 (0.20–0.97) | 0.040 |
| Tumor EBV (positive vs. negative) | 0.61 (0.24–1.60) | 0.312 | 0.89 (0.37–2.18) | 0.803 | ||||
HR Hazard ratio, CI Confidence interval, Tx Treatment, NLR Neutrophil–lymphocyte ratio, EBV Epstein-Barr Virus